Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Employees

1,017

Sector

Biotechnology & Medical Research

Calendar

Feb. 11 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-12	220.42 $	+4.88%	1,467,485
25-12-11	210.16 $	+4.43%	1,531,945
25-12-10	201.24 $	+2.34%	1,124,118
25-12-09	196.63 $	-5.06%	894,673

Delayed Quote Nasdaq, December 15, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

187.78EUR

Average target price

222.17EUR

Spread / Average Target

+18.32%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-15 pm EST			5-day change	1st Jan Change
213.24 ^USD	-3.26%		+2.95%	+54.89%

Dec. 12	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week	MT
Dec. 09	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT

Capitalization	11.47B 13.48B 10.73B 10.08B 18.56B 1,223B 20.31B 125B 48.39B 576B 50.59B 49.5B 2,093B	P/E ratio 2025 *	-56.4x	P/E ratio 2026 *	48.3x
Enterprise value	11.32B 13.31B 10.59B 9.95B 18.32B 1,207B 20.04B 124B 47.76B 569B 49.92B 48.86B 2,065B	EV / Sales 2025 *	15.8x	EV / Sales 2026 *	8.59x
Free-Float	97.58%	Yield 2025 *	-	Yield 2026 *	-

Dec. 12	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week	MT
Dec. 09	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
Dec. 04	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT
Nov. 26	European Equities Close Higher in Wednesday Trading; ECB Warns Tariff Exposure Could Strain Banks	MT
Nov. 26	European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading	MT
Nov. 26	Ascendis Pharma Says FDA Extended Review Period for TransCon CNP in Children With Achondroplasia by Three Months	MT
Nov. 25	US FDA extends review of Ascendis Pharma's therapy for children with dwarfism	RE
Nov. 25	European Equities Traded in the US as American Depositary Receipts Turn Sharply Higher in Tuesday Trading	MT
Nov. 20	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
Nov. 17	Ascendis Pharma A/S Announces Results of Pivotal Approach Trial of Transcon CNP (Navepegritide) in Children with Achondroplasia Published in Jama Pediatrics	CI
Nov. 17	European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading	MT
Nov. 14	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
Nov. 12	Ascendis Pharma A/S, Q3 2025 Earnings Call, Nov 12, 2025

Oct. 17	Raymond James Initiates Ascendis Pharma A/S at Strong Buy	MT
Oct. 08	Ascendis Pharma Submits Marketing Authorization Application for TransCon CNP in Europe	MT
Oct. 08	RBC Raises Price Target on Ascendis Pharma to $240 From $230, Keeps Outperform, Speculative Risk	MT
Sep. 22	Ascendis Pharma's Yorvipath Faces No Threat From MBX Biosciences's Canvuparatide, Wedbush Says	MT
Aug. 08	Ascendis Pharma's Q2 Revenue Driven by Strong Demand for Hypoparathyroidism Drug Yorvipath, Bank of America Says	MT

Ascendis Pharma A/S Stock

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Valuation: Ascendis Pharma A/S

Chart: Ascendis Pharma A/S

Latest news: Ascendis Pharma A/S

Last Transcript: Ascendis Pharma A/S

Analysts' recommendations: Ascendis Pharma A/S

Press Releases: Ascendis Pharma A/S

News in other languages: Ascendis Pharma A/S

Quotes and Performance

Course Extremes

Managers and Directors: Ascendis Pharma A/S

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Nov. 25	Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia	AQ
Nov. 17	Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics	AQ
Nov. 12	Ascendis Pharma Reports Third Quarter 2025 Financial Results	AQ
Nov. 07	New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism	AQ
Nov. 05	Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025	AQ

Nov. 11	Agenda van bedrijfsresultaten voor de week van 10 tot 14 november 2025: Chinese technologie, CoreWeave, Alstom en Vallourec in aantocht
Feb. 13	En direct des marchés : EssilorLuxottica brille encore, Alibaba flambe, Chevron taille dans ses effectifs
Feb. 13	Insubmersibles
Jan. 14	En direct des marchés : le TikTok de Musk, Lindt et Cucinelli publient, Amundi temporise en Italie
Jan. 14	Trump essaie la carotte après le bâton

1 day	-3.26%
1 week	+2.95%
Current month	+0.43%
1 month	-1.53%
3 months	+9.57%
6 months	+19.99%
Current year	+54.89%

1 week	192.28	229.94
1 month	192.28	229.94
Current year	118.03	229.94
1 year	118.03	229.94
3 years	64.33	229.94
5 years	61.58	229.94
10 years	11.92	229.94

Manager	Title	Age	Since
Jan Mikkelsen CEO	Chief Executive Officer	66	2007-11-30
Scott Smith DFI	Director of Finance/CFO	52	2016-08-07
Stina Singel CTO	Chief Tech/Sci/R&D Officer	52	2020-04-30

Director	Title	Age	Since
Jan Mikkelsen BRD	Director/Board Member	66	2007-11-30
Albert Cha CHM	Chairman	53	2021-05-27
Lisa Bright BRD	Director/Board Member	58	2017-03-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ASCENDIS PHARMA A/S	-3.26%	+2.95%	+56.11%	+79.18%	13.47B
LONZA GROUP AG	+1.63%	-3.68%	-1.80%	+10.15%	45.43B
IQVIA HOLDINGS INC.	+0.62%	-0.98%	+12.34%	+4.40%	37.85B
BEONE MEDICINES AG	-2.63%	-4.85%	+76.19%	+49.42%	35.31B
CELLTRION, INC.	+0.54%	+2.45%	+6.04%	+17.19%	27.66B
MEDPACE HOLDINGS, INC.	+0.22%	+1.81%	+59.87%	+171.67%	15.72B
REVOLUTION MEDICINES, INC.	+0.10%	-1.32%	+76.69%	+229.03%	15.26B
ICON PUBLIC LIMITED COMPANY	-1.18%	+1.25%	-9.70%	-3.39%	14.25B
IONIS PHARMACEUTICALS, INC.	-1.31%	-2.15%	+109.34%	+108.80%	13.09B
TEMPUS AI, INC.	-2.75%	-10.86%	+72.19%	-	12.56B
Average	-0.53%	-0.81%	+45.73%	+74.05%	23.06B
Weighted average by Cap.	-0.23%	-1.42%	+36.03%	+52.66%

	2025 *	2026 *
Net sales	715M 840M 668M 628M 1.16B 76.24B 1.27B 7.8B 3.02B 35.89B 3.15B 3.08B 130B	1.29B 1.52B 1.21B 1.13B 2.09B 138B 2.28B 14.08B 5.44B 64.8B 5.69B 5.57B 235B
Net income	-186M -219M -174M -164M -301M -19.86B -330M -2.03B -785M -9.35B -821M -803M -33.97B	222M 261M 207M 195M 359M 23.65B 393M 2.42B 935M 11.14B 978M 957M 40.46B
Net Debt	-150M -176M -140M -132M -243M -15.99B -265M -1.64B -632M -7.53B -661M -647M -27.34B	-389M -457M -363M -341M -629M -41.44B -688M -4.24B -1.64B -19.51B -1.71B -1.68B -70.88B